CCL20-SPECIFIC ANTIBODIES FOR CANCER THERAPY

• US 20110123542A1
• Filed: 06/24/2009
• Published: 05/26/2011
• Est. Priority Date: 06/24/2008
• Status: Abandoned Application

• Current Assignee: Hadasit Medical Research Services and Development Limited
• Original Assignee: Hadasit Medical Research Services & Development Ltd (Hadassah, The Women's Zionist Organization of America, Inc.)
• Inventors: Peled, Amnon, Beider, Katia
• Application Number:
  US13/000,991
• Publication Number:
  US 20110123542A1
• Time in Patent Office: Days
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07K 16/24 against cytokines, lymphokines or interferons

Abstract

The invention is directed to the field of cancer therapy, specifically to the use of anti-CCL20 antibodies for the treatment of neoplastic disorders. The invention provides compositions and methods useful for the treatment of CCR6 and CX-CR4 expressing tumors.

Claims

1. A method for treating a CCL20 dependent cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a CCL20-neutralizing antibody.

2. The method according to claim 1 for inhibiting tumor growth or tumor progression in the subject.

3. The method according to claim 1 for inhibiting tumor vascularization in the subject.

4. The method according to claim 1 for inducing or enhancing tumor regression in the subject.

5. The method according to claim 1, wherein at least a portion of the cells of the cancer express CCR6.

6. The method according to claim 1, wherein at least a portion of the cells of the cancer express CXCR4.

7. The method according to claim 1, wherein at least a portion of the cells of the cancer are characterized by surface expression of CCR6 and CXCR4.

8. The method according to claim 1, wherein the cancer is selected from glioma, leukemia, uterine cancer, lymphoma, neuroblastoma, pancreatic cancer, prostate cancer, clear cell renal carcinoma, colon cancer, colorectal cancer, lung cancer, breast cancer and melanoma.

9. The method of claim 8, wherein the cancer is prostate cancer.

10. The method of claim 8, wherein the cancer is colon cancer.

11. The method according to claim 1, wherein the antibody is MAB360.

12. The method according to claim 1, wherein the antibody has the same specificity as MAB360, or wherein said antibody has at least an antigen-binding fragment of MAB360.

13. The method according to claim 1, wherein the antibody is administered to the subject by injection or infusion.

14. A method of inhibiting, preventing or reducing metastasis of a CCL20 dependent tumor in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a CCL20-neutralizing antibody.

15. The method of claim 14, wherein the subject has a tumor expressing CCR6 and/or CXCR4 on at least a portion of the cells of the tumor.

16. The method according to claim 14, wherein the antibody is MAB360.

17. The method according to claim 14, wherein the antibody has the same specificity as MAB360, or wherein said antibody has at least an antigen-binding fragment of MAB360.

18. The method according to claim 14, wherein the antibody is administered to the subject by injection or infusion.

19-24. -24. (canceled)

25. A kit comprising a CCL20 neutralizing antibody, optionally formulated with at least one pharmaceutically acceptable excipient, and instructions for administering the antibody to a subject afflicted with cancer

26. The kit of claim 25, wherein the cancer is a CCL20 dependent cancer.

27. The kit of claim 26, wherein the cancer is selected from glioma, leukemia, uterine cancer, lymphoma, neuroblastoma, pancreatic cancer, prostate cancer, clear cell renal carcinoma, colorectal cancer, lung cancer, breast cancer and melanoma.

28. A kit according to claim 25, wherein the antibody is MAB360, an antibody having the same specificity as MAB360, or an antibody having at least an antigen-binding fragment of MAB360.